Xin Tao

With a strong understanding of life sciences, Xin Tao works closely with clients in the food and drug industries to navigate the evolving regulatory environments and develop innovative strategies to commercialize products made with emerging technologies in the United States.

Xin's previous work experience as a lab research biochemist informs his science-based food and drug law practices. His unique ability in understanding and interpreting the complex scientific issues as they relate to the governing legal and regulatory requirements helps clients with all phases of product development, manufacturing, and marketing. His practice focuses on novel food and drug applications that require U.S. Food and Drug Administration (FDA) review and FDA Current Good Manufacturing Practices (cGMP) compliance for foods, dietary supplements, and pharmaceuticals. Xin has extensive experience advising companies and investors on developing and marketing alternative plant proteins, microbial and animal cell-based technologies.    

Born and raised in China, Xin is well-equipped to assist global companies to adapt to China's National Medical Products Administration's (NMPA), formerly known as China Food and Drug Administration (CFDA), ever-changing regulatory regime.

During law school, Xin worked as a regulatory scientist at an international law firm and served as an executive editor of the Georgetown Environmental Law Review.